Because of the involvement of IL-25 in the pathophysiology of allergic conjunctivitis, targeting IL-25 or IL-25R on effector cells is a potential modality for attenuating IL-25 mediated type 2 immune response [162]. The gene discussed is IL25; the disease is atopic conjunctivitis.